{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:19:17Z","timestamp":1791533957563,"version":"4.3.4"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Premenopausal patients with breast cancer are treated with gonadotropin-releasing hormone agonist (GnRHa) therapy to suppress ovarian function. Therapy requires subcutaneous or intramuscular injection and is routinely administered during clinic visits.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the feasibility and acceptability of a telemedicine-supported home-injection program for patients with breast cancer receiving GnRHa therapy.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This quality improvement study was conducted between October 2024 and August 2025. Patients were followed up for up to 2 home injections over a 6-month period. Patients were recruited from 4 outpatient medical oncology practices at a comprehensive cancer center. Eligible participants were adults with breast cancer who used the patient portal and had ongoing therapy with a GnRHa.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients received in-clinic training from nursing staff on injection preparation and administration. Telemedicine nursing visits for supervision of home injections were optional.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was feasibility, assessed by home-injection completion rates. Patient and clinician satisfaction were assessed using net promotor scores and rates of continued home injection following the pilot. Patients were invited to participate in semi-structured exit interviews.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 105 eligible patients, 54 chose to participate, and 24 obtained coverage to dispense medication for self-injection at home. Among the 24 participants (median [range] age, 44 [33-53] years) all were female. All participants were trained in GnRHa intramuscular administration; 10 of 20 (50.0%) had no prior injection experience. Overall, of the 24 participants, 23 (95.8%) successfully completed at least 1 injection at home, 19 (79.2%) completed 2, and 18 (75.0%) opted to continue home administration beyond the study end. Only 1 patient discontinued due to challenges related to injection administration and telemedicine scheduling. Of 17 patients, time savings (15 [88.2%]) and convenience (13 [76.5%]) were cited as key benefits. The model was strongly endorsed, according to a net promoter score of 69 for patients and of 61 for clinicians. Of the 54 patients who chose to participate, 19 (35.2%) were unable to proceed due to a lack of insurance approval for home administration of the eligible medication, and among 30 patients who received insurance authorization, 18 (60.0%) incurred a copayment for the medication when injection coverage shifted from clinic-based administrations to home-based administrations.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this quality improvement study of a telemedicine-supported home injection model for women with breast cancer, strong feasibility was demonstrated by high injection completion rates and acceptability by participants. The findings suggest that insurance approval and the copayments associated with at-home, but not in-clinic, administration were an impediment to participation and need to be addressed before scaling.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.29406","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:30:33Z","timestamp":1787326233000},"page":"e2629406","source":"Crossref","is-referenced-by-count":1,"title":["A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Charlotte D.","family":"Malling","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Bange","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Marcinkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Andronico","sequence":"additional","affiliation":[{"name":"Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bonenfant","sequence":"additional","affiliation":[{"name":"Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Budrock","sequence":"additional","affiliation":[{"name":"Division of Advanced Practice Providers, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Sadowsky","sequence":"additional","affiliation":[{"name":"Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Lee-Teh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lake","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahil D.","family":"Doshi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chimonas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilad","family":"Kuperman","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Polubriaginof","sequence":"additional","affiliation":[{"name":"Office of the Chief Medical Officer, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Stetson","sequence":"additional","affiliation":[{"name":"TigerConnect, El Segundo, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A.","family":"Traina","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sanford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Schrag","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S.","family":"Panageas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"10","key":"zoi260809r1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi260809r2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer.","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi260809r3","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials.","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260809r4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/OP-24-00502","article-title":"Clinical management of ovarian function suppression in premenopausal women with breast cancer: a survey of members of ASCO.","volume":"21","author":"Kelly","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"zoi260809r5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1007\/s12282-020-01205-w","article-title":"A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.","volume":"28","author":"Kurebayashi","year":"2021","journal-title":"Breast Cancer"},{"issue":"7","key":"zoi260809r6","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi260809r7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S1470-2045(25)00006-3","article-title":"Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study.","volume":"26","author":"Ahn","year":"2025","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi260809r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.47930","article-title":"Time toxicity of cancer care\u2014a call to action.","volume":"8","author":"Doshi","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi260809r9","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"issue":"2","key":"zoi260809r10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.xfre.2023.01.008","article-title":"Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine.","volume":"4","author":"Saleh","year":"2023","journal-title":"F S Rep"},{"issue":"16","key":"zoi260809r11","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1200\/JCO.2022.40.16_suppl.1515","article-title":"Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic.","volume":"40","author":"Dang","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi260809r12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7399","article-title":"QIM26-312: a scalable model for oncology home leuprolide injections.","author":"Shah","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"zoi260809r13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"2","key":"zoi260809r16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"zoi260809r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"12","key":"zoi260809r18","first-page":"46","article-title":"The one number you need to grow.","volume":"81","author":"Reichheld","year":"2003","journal-title":"Harv Bus Rev"},{"issue":"6","key":"zoi260809r20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014788.pub2","article-title":"Gonadotropin-releasing hormone analogues for endometriosis.","volume":"6","author":"Veth","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"zoi260809r23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1046\/j.1464-410x.2000.00910.x","article-title":"Patient self-injection: a new approach to administering luteinizing hormone-releasing hormone analogues.","volume":"86","author":"Hamm","year":"2000","journal-title":"BJU Int"},{"issue":"1","key":"zoi260809r24","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.21","article-title":"Enhancing study recruitment through implementation of an opt-out, cold contact process with consideration for autonomy, beneficence and justice.","volume":"7","author":"Pittman","year":"2023","journal-title":"J Clin Transl Sci"},{"issue":"12","key":"zoi260809r25","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41395-018-0151-3","article-title":"A randomized controlled trial of opt-in versus opt-out colorectal cancer screening outreach.","volume":"113","author":"Mehta","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"zoi260809r26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/0890117116671673","article-title":"A randomized controlled trial of opt-in versus opt-out enrollment into a diabetes behavioral intervention.","volume":"32","author":"Aysola","year":"2018","journal-title":"Am J Health Promot"},{"issue":"29","key":"zoi260809r27","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.20.00642","article-title":"Cancer disparities and health equity: a policy statement from the American Society of Clinical Oncology.","volume":"38","author":"Patel","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi260809r28","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment.","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260809r29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014861.pub2","article-title":"Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.","volume":"4","author":"Grobler","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"zoi260809r31","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update.","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi260809r32","doi-asserted-by":"publisher","DOI":"10.1056\/CAT.25.0168","article-title":"Cancer CARE (Connected Access and Remote Expertise) Beyond Walls\u2014safety, feasibility, and patient experience of home-based chemotherapy.","author":"Dronca","year":"2026","journal-title":"NEJM Catal"},{"issue":"6","key":"zoi260809r33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1200\/OP-25-00955","article-title":"Subcutaneous immunotherapy in cancer: where we are now, what it changes, and what to watch next.","volume":"22","author":"Petrelli","year":"2026","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"zoi260809r34","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260809r35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.annonc.2024.09.002","article-title":"Subcutaneous versus intravenous nivolumab for renal cell carcinoma.","volume":"36","author":"Albiges","year":"2025","journal-title":"Ann Oncol"},{"issue":"16","key":"zoi260809r36","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2024.42.16_suppl.4532","article-title":"Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.","volume":"42","author":"Bourlon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260809r38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines.","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"issue":"11","key":"zoi260809r39","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","article-title":"The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: a narrative review.","volume":"40","author":"Antalfy","year":"2023","journal-title":"Adv Ther"},{"key":"zoi260809r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2026.115030","article-title":"From vial to prefilled delivery devices in autoimmune diseases: exploring the formulation and technological pharmaceutical challenges.","volume":"222","author":"Vieira","year":"2026","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"zoi260809r41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jamaoncol.2019.5358","article-title":"The future of cancer care in the United States\u2014overcoming workforce capacity limitations.","volume":"6","author":"Shulman","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi260809r42","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1200\/OP-25-00144","article-title":"Where have we been and where are we going? The state of the hematology and medical oncologist workforce in America.","volume":"21","author":"Kirkwood","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"9","key":"zoi260809r43","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaoncol.2025.2331","article-title":"Challenges and opportunities for the US oncology workforce.","volume":"11","author":"Shulman","year":"2025","journal-title":"JAMA Oncol"},{"key":"zoi260809r19","author":"Charmaz","year":"2012"},{"key":"zoi260809r22","volume-title":"NEJM Catal","author":"Laughlin","year":"2020"},{"key":"zoi260809r14","unstructured":"Memorial Sloan Kettering Cancer Center. How to give an intramuscular injection of leuprolide acetate (Lupron Depot\u00ae). Accessed July 15, 2026. https:\/\/www.mskcc.org\/cancer-care\/patient-education\/intramuscular-injection-of-lupron"},{"key":"zoi260809r15","unstructured":"Memorial Sloan Kettering Cancer Center. How to give yourself a subcutaneous injection using a prefilled syringe. Accessed July 15, 2026. https:\/\/www.mskcc.org\/cancer-care\/patient-education\/how-give-yourself-subcutaneous-injection-using-prefilled-syringe"},{"key":"zoi260809r21","unstructured":"National Library of Medicine. Label: Lanreotide acetate injection. DailyMed. Updated September 1, 2024. Accessed May 28, 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=11da176a-99bc-4ada-8b3f-6bd2b37a6313"},{"key":"zoi260809r30","unstructured":"Carpenter? A. What is a good net promoter score? QualtricsXM. February 22, 2021. Accessed February 18, 2026. https:\/\/www.qualtrics.com\/articles\/customer-experience\/good-net-promoter-score"},{"key":"zoi260809r37","unstructured":"Comparison of in-home versus in-clinic administration of subcutaneous nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) program. ClinicalTrials.gov identifier: NCT06265285. Updated June 9, 2026. Accessed July 15, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06265285"},{"key":"zoi260809r44","unstructured":"MATCH-UP: Making telehealth-delivery of cancer care at home effective and safe-upscaled: a pragmatic cluster randomized trial. ClinicalTrials.gov identifier: NCT06954337. Updated April 1, 2026. Accessed July 15, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06954337"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853159\/malling_2026_oi_260809_1786722273.95515.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:30:38Z","timestamp":1787326238000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.29406","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}